The human gut is colonized by commensal microorganisms, predominately bacteria that have coevolved in symbiosis with their host. The gut microbiota has been extensively studied in recent years, and many important findings on how it can regulate host metabolism have been unraveled. In healthy individuals, feeding timing and type of food can influence not only the composition but also the circadian oscillation of the gut microbiota. Host feeding habits thus influence the type of microbe-derived metabolites produced and their concentrations throughout the day. These microbe-derived metabolites influence many aspects of host physiology, including energy metabolism and circadian rhythm. Peroxisome proliferator-activated receptors (PPARs) are a group of ligand-activated transcription factors that regulate various metabolic processes such as fatty acid metabolism. Similar to the gut microbiota, PPAR expression in various organs oscillates diurnally, and studies have shown that the gut microbiota can influence PPAR activities in various metabolic organs. For example, short-chain fatty acids, the most abundant type of metabolites produced by anaerobic fermentation of dietary fibers by the gut microbiota, are PPAR agonists. In this review, we highlight how the gut microbiota can regulate PPARs in key metabolic organs, namely, in the intestines, liver, and muscle. Knowing that the gut microbiota impacts metabolism and is altered in individuals with metabolic diseases might allow treatment of these patients using noninvasive procedures such as gut microbiota manipulation.-Oh, H. Y. P., Visvalingam, V., Wahli, W. The PPAR-microbiota-metabolic organ trilogy to fine-tune physiology. FASEB J. 33, 9706-9730 (2019). www.fasebj.org KEY WORDS: circadian rhythm • intestines • liver • muscle 1 These authors contributed equally to this work.
Metabolic syndrome is defined by a constellation of metabolic abnormalities that predispose an individual to cardiovascular diseases and type 2 diabetes mellitus (T2DM) (1, 2) . These metabolic abnormalities include hyperlipidemia, hypertension, central obesity, and hyperglycemia (3) . Although there is no clear etiology, factors such as overweight, obesity, and a sedentary lifestyle have been reported to be some of the causes for developing the syndrome (2, 3) . Epidemiologic studies suggest that active smoking is also associated with metabolic syndrome (4) . Metabolic syndrome has become more prevalent among the world population, and it is reported that 25% of adults in the world now have this syndrome (5) . The International Diabetes Federation reported that the risk of people developing T2DM is 5 times greater and the risk of a heart attack or a stroke is 2 times greater when they have metabolic syndrome (5) . It was estimated in 2017 that the total healthcare expenditure on diabetes worldwide for ages 20-79 would reach the alarming amount of U.S. $727 billion, an 8% increase from the 2015 estimate (6) . Without any effective intervention, the amount spent on diabetes care is projected to increase by another 7% to a total of U.S. $778 billion by 2045 (6) . ABBREVIATIONS: ADRP, adipose differentiation-related protein; ALD, adrenoleukodystrophy; ANGPTL4, angiopoietin-like protein-4; AP-1, activator protein 1; ASBT, bile acid transporter; BMAL1, brain and muscle aryl hydrocarbon receptor nuclear translocator-like 1; BSH, bile salt hydrolase; CA, cholic acid; CDCA, chenodeoxycholic acid; Clock, circadian locomoter output cycles protein kaput; CoA, coenzyme A; CPT, carnitine palmitoyltransferase; Cry, cryptochrome; CYP, cytochrome P450; Dec, differentiated embryonic chondrocyte; DEFB, defensin b; ECBSH, E. coli producing BSH; FDA, U.S. Food and Drug Administration; FFAR, free fatty acid receptor; FMT, fecal microbiota transplantation, FXR, farnesoid X receptor; GF, germ free; GPR, G-protein receptor; HDAC, histone deacetylase; HFD, high-fat diet; IEC, intestinal epithelial cell; ipRGC, intrinsically photoreceptive retinal ganglion cell; LPL, lipoprotein lipase; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; OCTN, organic cation transporter; Per, period; PGC-1, PPAR-g coactivator-1; PGlyRP3, peptidoglycan recognition protein 3; PPAR, peroxisome proliferator-activated receptor; PPRE, peroxisome proliferator response element; PSA, polysaccharide A; REV-ERB, reverse-erb nuclear receptor; Ror, retinoic acid-related orphan receptor; SB, small bowel; SCFA, short-chain fatty acid; SCN, suprachiasmatic nucleus; SPF, specific pathogen free; T2DM, type 2 diabetes mellitus; TCAC, tricarboxylic acid cycle; T h , T helper; TZD, thiazolidinedione; UCP2, uncoupling protein 2; X-ALD, X-linked ALD With metabolic syndrome placing a great burden primarily on healthcare, much research and many clinical trials have been conducted to tackle this global epidemic. Many studies have tried to elucidate the causes of obesity, and emerging studies have identified the gut microbiota as a potential key factor in obesity and the development of metabolic disorders like T2DM (1, (7) (8) (9) (10) (11) (12) . In addition, the peroxisome proliferator-activated receptors (PPARs), a group of nuclear receptors known to play a heavy role in metabolism, have been extensively studied over the past decades, highlighting their diverse functions in metabolism, inflammation, wound healing, and cancer. They are now considered 1 of the popular targets in the treatment of metabolic diseases, with pharmaceutical companies actively formulating and conducting clinical trials on new PPAR drugs. Both the gut microbiota and PPARs have been noted to oscillate in a diurnal pattern, demonstrating a level of involvement of the circadian rhythm. In recent years, a considerable number of findings have revealed that the crosstalk between PPARs, the gut microbiota, and the circadian rhythm can influence the development of metabolic diseases.
This review aims to consolidate the pertinent articles that have been written on these 3 topics, with a brief description of each field, and present a balanced overview on how the microbiota can possibly influence peripheral daily rhythm through PPARs and how they in turn influence metabolic organs, namely, the gut, liver, and skeletal muscle.
THE GUT MICROBIOTA
The earliest studies of the presence of gut microbes in humans, dated back to the late 17th century, were by the Dutch scientist Antony van Leeuwenhoek, who discovered gut microbiota in his excrement. With more advanced laboratory techniques, the importance of host-microbe interactions in the human holobiont is now progressively being uncovered (13) . The human body is colonized by commensal microorganisms, predominately bacteria that have coevolved in symbiosis with their host. Commensal bacteria colonize primarily on epithelial and mucosal surfaces that typically line the skin, vagina, gastrointestinal tract, and respiratory tract, with the largest number reported residing in the gastrointestinal tract (14) . Analysis of the human gut showed that it is colonized by about 500-1000 species of bacteria (15, 16) . These trillions of bacteria residing in the gut have a collective genome containing 100 times more genes than the host human genome (17) .
The colonization of the human gut by microbiota occurs at birth when the infant is exposed to the vaginal microflora when passing through the birth canal (18) . Subsequently, various environmental factors such as diet, level of sanitation, and antibiotic exposure can alter the composition of the gut microbiome, and by 1-2.5 yr of age, the intestinal microbiome resembles that of an adult (18, 19) . The gut microbiota of the adult human comprises mainly strict anaerobes, facultative anaerobes, and aerobes, with the strict anaerobes being the majority (19, 20) .
Despite the fact that the gut microbiota composition differs among individuals, it is reported to be dominated by 2 major phyla, mainly Bacteroidetes and the Firmicutes, whereas the less-abundant phyla such as Proteobacteria, Verrucomicrobia, Actinobacteria, Fusobacteria, and Cyanobacteria make up the rest of the gut microbiota (19, 21) . The composition of the bacterial population also varies with the intestinal segments. The bacilli class belonging to the Firmicutes phylum and Actinobacteria are commonly found in the small intestines, and the Bacteroidetes and Lachnospiraceae families belonging to the Firmicutes phylum are more prevalent in the colon (22) . In the murine gut, the dominant phyla are also shown to be Bacteroidetes and Firmicutes, although variation in the genera has been reported (12, 21, 23) . A meta-analysis comparing the 16S recombinant DNA sequenced from fecal samples of adult humans and mice revealed that although 79 genera are common to both human and mice, the relative abundance of most of the dominant genera for the human and mouse is different. The human gut has higher amounts of Prevotella, Faecalibacterium, and Ruminococcus, whereas Lactobacillus, Alistipes, and Turicibacterthe are found in higher abundance in the mouse gut (24) .
With mounting research suggesting that the gut microbiome has a greater role in health and metabolism, researchers are prompted to evaluate the possible diverse roles of gut microbiota, particularly using the mouse model (7, 18, (25) (26) (27) (28) (29) . A total of 5 important functions performed by the gut microbiota are further described below: control of gut development, regulation of host nutritional status and metabolism, deconjugation of bile acids, prevention of pathogenic colonization, and maintenance of gut immune function (18) .
In relation to gut development, studies researching the roles of the microbiota showed anatomic differences in the gut between germ-free (GF) mice and normal mice. The ceca of the GF mice are 4-8 times larger because of the buildup of mucus and undigested fiber, causing functional deficits in the gastrointestinal tract and even in the reproductive organs (30) . Development of the small bowel (SB) was also stunted, leading to a smaller surface area with irregular villi and reduced gut motility (19, 30) . Vasculature of the SB is promoted by a particular anaerobe, Bacteroides thetaiotaomicron, which promotes angiogenesis via the protein angiogenin-3 and modulates the peristaltic function of the gut (31) . Additionally, the microbiota is capable of synthesizing many different types of polyamines, a group of organic polycationic compounds such as putrescine, spermidine, and spermine. These polyamines are capable of interacting with negatively charged compounds such as DNA, RNA, and proteins to influence cell growth and survival (25) . Lastly, the gut microbiota also maintains the integrity of the intestinal epithelial tight junctions, preventing a leaky gut (19) .
With regard to host nutritional status, the gut microbiota can regulate it by augmenting the extraction of energy from otherwise undigested food (7, 20) . The microbiota enhances energy absorption by fermenting the nondigestible polysaccharides and produces short-chain fatty acids (SCFAs) as byproducts that serve as additional energy sources for both the residing gut microbiota and the intestinal epithelium, for which butyrate is the main energy source (27, 32) . Other SCFAs like acetate and propionate are absorbed into the circulation and used in gluconeogenesis and lipogenesis in the liver, muscle, and adipose tissue (33, 34) . The gut microbiota's direct role in metabolism is clearly demonstrated in GF mice, which were subsequently conventionalized with the microbiota from normal adult mice (11) . Conventionalized GF mice had a 60% increase in body fat despite a reduction in food intake for 2 wk (11). The gain in body fat can be explained by a mechanism involving the gut microbiota that suppresses angiopoietin-like protein-4 (ANGPTL4), an inhibitor of lipoprotein lipase (LPL) (11, 35) . In GF mice, the absence of microbiota results in a higher level of ANGPTL4, which in turn reduces the triglyceride storage by inhibiting LPL (35) . In conventionalized mice, ANGPTL4 levels are reduced, causing LPL levels to rise and, as a result, promoting the storage of triglycerides (11) . Another mechanism by which the gut microbiota can influence the levels of triglycerides is through the modulation of choline. Choline is an essential nutrient used by the liver for the synthesis of phosphatidylcholine (36) . Phosphatidylcholine in turn is an important molecule essential for the formation of many biologic components, including the lipoproteins. The gut microbiota is capable of regulating the bioavailability of choline by converting diet-derived choline to trimethylamine, hence indirectly regulating the biosynthesis of lipoproteins in the liver (9) . It is expected that any perturbances in the gut microbiota will disrupt the choline level in the body and the synthesis of lipoproteins (36, 37) . Indeed, studies have indicated that reduced hepatic phosphatidylcholine impairs the export of triglyceride-containing very LDL from the liver, leading to triglyceride accumulation and progression of fatty liver (38) (39) (40) (41) (42) . In addition, production of trimethylamine-Noxide from the metabolism of phosphatidylcholine by the gut microbiota has been associated with increased risk of cardiovascular diseases (43, 44) .
The third function of the microbiota is the deconjugation and metabolism of bile acids. The primary bile acids produced by the liver in humans are cholic acid (CA) and chenodeoxycholic acid (CDCA), which are conjugated by the liver with 1 of 2 aa (taurine or glycine) (45, 46) . The bile acids are first stored in the gallbladder before being secreted into the duodenum via the bile duct. Approximately 95% of these bile acids are reabsorbed and enter the enterohepatic circulation. The bulk of the bile acids are absorbed in their conjugated form by facilitated transport through the ileum apical sodium-dependent bile acid transporter (ASBT), although the absorption of unconjugated bile acids is also possible in smaller quantity by passive reabsorption (45) . However, the gut microbiota in the SB can reduce the ASBT-mediated reuptake of bile acids by deconjugating (removing the taurine or glycine from) the bile acids. This deconjugation process is carried out by enzymes called bile salt hydrolases (BSHs) produced by the microbiota (45, 47, 48) . Deconjugated bile acids, unable to be reabsorbed, enter the colon, where the bulk portion of them are then metabolized into secondary bile acids by the gut microbiota through enzymatic processes such as dehydroxylation, epimerization, and oxidation (45) . In addition to the breakdown of bile acids, the gut microbiota is also involved in the regulation of the liver enzymes responsible for the synthesis and conjugation of bile acids as well as the synthesis of taurine and regulation of ASBT (49) .
Interestingly, bile acid metabolism is also linked with lipid metabolism in a microbiota-dependent manner. Bile acids aid in fat digestion by emulsifying lipids, including cholesterol. The microbiota, by interfering with the enterohepatic circulation of the bile acids, can regulate the availability of bile acids for lipid emulsification (50) . The microbiota also helps to excrete excess cholesterol by breaking it down into the nonabsorbable coprostanol, which is then passed out via the feces (51) . Alternatively, the cholesterol molecule directly adsorbs onto the microbiota, preventing absorption by the host (50) . Through these mechanisms, the microbiota maintains (if not lowers) plasma cholesterol levels (50, 51) .
The physical presence of the microbiota itself helps to prevent colonization of other pathogenic bacteria via a variety of mechanisms such as competing for nutrients and preventing the pathogens from adhering to the intestinal wall (19, 52) . The commensals even have the ability to induce the expression of antimicrobial peptides, which protect the host from invading pathogens as well as overgrowth of commensals (19) . These features contribute to maintaining the composition and balance of the gut microbiota. A perturbed microbiota (or dysbiosis) can result in numerous diseases. A good example of this would be diarrhea associated with antibiotic use and the more severe form, pseudomembranous colitis (18, 26) . Both conditions are caused by increased Clostridium difficile spore germination due to higher primary bile acid content (53, 54) . Other pathogenic manifestations of dysbiosis also include necrotizing enterocolitis in newborns and small-bowel bacterial overgrowth when colonic bacteria begin to colonize in the SB (18) . Recent studies have also begun to shed more light on the immunologic interaction between the host and microbiota and how dysbiosis is implicated in the pathogenesis of diseases like inflammatory bowel disease, irritable bowel syndrome, and even colon cancer (18, 19, 25) .
To get a better understanding of the pathogenesis of these diseases, it is essential to understand the fifth role of the gut microbiota: development and maintenance of the mucosal immune system. From the perspective of the host, the mucosal immune system has to tolerate the existing commensal flora without mounting an excessive immune response but at the same time prevent overcolonization and systemic spread of the bacteria. Interestingly, it is the gut microbiota that is closely involved in the balance of these 2 functions of the mucosal immune system. The absence of microbiota can itself lead to a compromised immune system structure. Studies have shown that GF mice have underdeveloped lymphoid tissues, resulting in suboptimal mucosal immunity (19, 55) . In fact, GF mice showed a lack of CD4 + T-cell expansion, resulting in a major deficit in the host's immunity. The defect, however, was completely reversed with the use of polysaccharide A (PSA), an antigen of B. fragilis. Administration of PSA or B. fragilis promoted the expansion of CD4 + T cells by PSA presented to immature T lymphocytes by dendritic cells in the local lymph nodes, known as mesenteric lymph nodes (56) .
This leads us to the microbiota's involvement in the development of the immune system. A study that involved the colonization of GF pigs with a nonpathogenic strain of Escherichia coli showed an initial inflammatory immune response, which was then inhibited after 5-10 d (14, 57, 58) . Another study showed that certain Lactobacillus species have immunomodulation effects on dendritic cells that influence the maturation of naive T helper (T h ) cells. Inflammatory cytokines released by the dendritic cells can modulate the maturation of naive T h cells into T h 1, T h 2, or T h 3 cells based on the type and concentration of cytokines. It is demonstrated that exposure to different species of Lactobacillus can modulate various levels of cytokine production from the dendritic cells such as IL-12, IL-6, IL-10 and TNF-a, and hence maturation of T h 1, T h 2, and T h 3 cells can be regulated by the gut microbiota (59, 60) . B. thetaiotaomicron suppresses the activation of the proinflammatory protein complex NF-kb through a PPAR-g-dependent mechanism that will be explained in later sections (61) .
It has also been highlighted that the microbial metabolites mentioned earlier are involved in the maintenance of the mucosal immune system. SCFAs promote antiinflammatory responses in immune cells via various mechanisms such as inhibiting histone deacetylases (HDACs) and NF-kb and down-regulating TNF-a (25) . Polyamines promote epithelial barrier function by increasing the expression of intercellular junction proteins, including occludin, zonula occludens 1, and E-cadherin (25) . Impairments in the epithelial barrier have been associated with diseases such as inflammatory bowel disease (Crohn's disease and ulcerative colitis), diabetes, obesity, and nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) (62) (63) (64) (65) (66) .
Despite so many advantages associated with having a gut microbiota, a plethora of studies have challenged the mutualistic relationship in the holobionts. Intriguingly, despite a reduction in daily food intake, conventionalized GF mice had a 60% higher body fat mass and developed insulin resistance within 2 wk (11). The fact that GF mice rarely develop diet-induced glucose intolerance and insulin resistance further supports the association of microbiota with metabolic disorders (67) . Other studies have shown that GF mice have lesser body fat and better glucose tolerance. For instance, a comparison made between GF mice and conventionally raised mice revealed that the former group had 40% less body fat despite consuming 29% more calories than the other group, which further supports microbiota being involved in extracting energy from ingested food (68) . In addition, altered gut microbiota composition might be linked to the pathogenesis of obesity and other metabolic disorders. GF mice colonized with microbiota derived from obese mice gained a significantly higher amount of total body fat within 2 wk compared with GF mice colonized with microbiota derived from lean mice, clearly demonstrating that the gut microbiome of obese mice is the causal factor in the amount of body fat gained (68) .
In a healthy host, the gut microbiota is fine-tuned such that the balance in its composition ensures homeostasis of its own niche (the intestinal mucosa) and indirectly regulates other metabolic organs by systemic circulation of bacteria-derived metabolites (19, 29, 30, 69, 70) . The importance of this balanced gut microbiota composition in host physiology and energy homeostasis is underscored by various reports indicating that patients with various metabolic disorders such as obesity, diabetes, and NAFLD have a perturbed gut microbiota (18, 27) . The role of the gut microbiota in energy homeostasis is further accentuated through its links with PPARs, which can be activated by bacteria-derived metabolites (71) . The hepatic gene expression correlation network of all 3 PPARs was significantly different between GF and conventional mice, reaffirming the interconnection between PPARs and the gut microbiome (72) .
PPARS
PPARs form a small family of ligand-activated transcription factors belonging to the nuclear receptor superfamily, which consists of 3 isotypes (71) that are known to be involved in diverse biologic processes vital for mammalian survival. Some commonly reported functions are in inflammation, reproduction, development, cell proliferation, cell specialization, and energy metabolism (lipids and carbohydrates) (73) (74) (75) .
In 1990, peroxisome proliferators had been shown to activate a mouse receptor in organs sensitive to peroxisome proliferators such as the liver and kidney (76) . A total of 3 isotypes of this PPAR were then discovered in Xenopus and named PPAR-a, PPAR-b, and PPAR-g in 1992 (77) .
As mentioned, PPAR-a was first identified in the mouse liver as a receptor that is activated by peroxisome proliferators, hence its name. Peroxisome proliferators refer to a group of chemicals such as industrial plasticizers, herbicides, and also hypolipidemic drugs (like clofibrate) that cause an increase in hepatic peroxisomes and liver hyperplasia in rodents, specifically (76) . It was postulated that this group of chemicals exerts its effects via a process that is similar to that of steroid hormones because these chemicals also prompted transcription of genes needed for peroxisomal b-oxidation of long-chain fatty acids (77) . PPAR-b was first identified in the oocytes of Xenopus (77). A closely related receptor to PPARs was later discovered in the mouse and was named PPAR-d, with the idea that there may be 4 PPAR isotypes (78, 79) . Subsequently, investigations and comparisons made between PPARs of chickens, mice, and Xenopus showed that the mammalian PPAR-d is the ortholog of the previously described amphibian PPAR-b; hence, this isotype was termed PPARb/d (78). PPAR-g was also first discovered in Xenopus, where it was found highly expressed in adipose tissue alongside PPAR-b/d (77). The PPAR-g protein is expressed in 2 isoforms: PPAR-g1 and PPAR-g2 (80) . A study showed that there are 6 mRNAs (namely, PPAR-g1-5 and PPAR-g7) that are generated in human macrophages as a result of differential promoter usage and alternative splicing (81) . However, more studies are necessary to reinforce this finding. PPAR-g1, -g3, -g5, and -g7 mRNA transcripts are then translated to the PPAR-g1 receptor, whereas PPAR-g2 mRNA yields the PPAR-g2 receptor (71, 80, 82) . The 3 PPAR genes are localized on the human chromosome 22, near the general region 22q12-q13.1 for PPAR-a (83) , chromosome 6 at the region 6p21.1-p21.2 for PPAR-b/d (84) , and chromosome 3 at position 3p25 for PPAR-g (85) . Conversely, the PPAR genes were mapped on the mouse chromosomes 15, 17, and 6 for PPAR-a, PPAR-b/d, and PPAR-g, respectively (86) .
PPARs, in parallel to other nuclear receptors, have a common canonical structure consisting of 4 main domains (namely, A/B, C, D, and E/F) (87). The general structure for all 3 PPAR isotypes is shown in Fig. 1 with a diagrammatic representation of each isotype and isoform. Differences in the amino acid sequences that make up each isotype's primary structure set them apart from one another and contribute to their differences in ligand specificity and functions. The ligand binding cavity of PPARs is made up of 34 residues, and 80% of these are identical across all 3 isotypes (88). The differences in the remaining amino acid residues determine the nature, structure, and function of each PPAR isotype. For example, in PPAR-a, valine at position 453 was identified to be the key amino acid residue that determines strong affinity for fibrates (89) . At the corresponding position in PPAR-b/d, a mutation of methionine to valine at position 417 resulted in an increased binding affinity to fibrate molecules, which are usually weak ligands in the wild-type PPAR-b/d receptor (89) .
Canonical activation of PPAR begins by binding with another nuclear receptor, the retinoid X receptor, to form a heterodimer, which then binds to peroxisome proliferator response elements (PPREs) (78) . The PPRE is a direct repeat of 2 core recognition motifs AGGTCA spaced by 1 nt with only a few exceptions and, thus, was termed DR-1 element (71) . In the absence of ligands, the PPAR:retinoid X receptor heterodimer is bound with corepressors such as nuclear receptor corepressors, HDAC, and G-protein pathway suppressor 2, which prevent transcription of the target genes. When a ligand binds to PPAR, the corepressors dissociate from the heterodimer, and coactivators such as PPAR-g coactivator-1 (PGC-1), the histone acetyltransferase p300, cAMP response element binding protein binding protein, and steroid receptor coactivator 1 are recruited to assemble an active transcription initiation complex on the promoter of target genes (2, 71, 90) . Thus, PPARs function as factors promoting the expression of specific target genes. The ligands that bind to PPARs and activate them can be categorized into natural and synthetic ligands ( Table 1) . Some of these synthetic ligands are used to treat dyslipidaemia and diabetes and have also shown anti-inflammatory properties (74, 78) .
In other instances, PPAR-a and -b/d have been reported to associate with heat shock proteins in the cytoplasm awaiting ligand activation (91) . A ligand-bound PPAR can also associate with other transcription factors such as p65 or c-proto-oncogene jun, each with its own downstream effects (2, 92, 93) . For example, the association of PPAR-g with p65 results in the inhibition of the NF-kB pathway, whereas PPAR-a association with c-jun results in the inhibition of the activator protein 1 (AP-1) signaling pathway (2, 92, 93) .
PPARs, considered highly medically relevant targets, have been extensively studied in the last few decades. Because of their prominent role in metabolism, PPARs have been implicated in the pathogenesis of metabolic syndrome and associated metabolic diseases. Although activation of PPARs by several synthetic drugs has been Each PPAR isotype has its own group of natural and synthetic ligands, although some ligands interact with .1 isotype. The natural ligands are either derived endogenously or from our diet (78, 95, 96, 267, 268) . PPAR ligands have been reviewed extensively (78, 95, 96, 267, 268) ; therefore, only general information is provided here.
considerably effective in treating and managing metabolic syndrome, some of the approved drugs have been retracted from the market or their usage has been curtailed because of harmful side effects (94) . Recently, some reviews have already discussed the exhaustive list of agonists and their clinical trial status for each PPAR isotype (95) (96) (97) (98) . Therefore, in this review, we will only briefly highlight a few of the promising new drugs that are still undergoing intensive evaluation in human clinical trials.
Pemafibrate (K-877; Kowa, Nagoya, Japan), 1 of the newest PPAR-a agonists, has been deployed under several independent clinical trials. Surpassing its U.S. Food and Drug Administration (FDA)-approved predecessor fenofibrate (the most commonly prescribed fibrate in the market), pemafibrate exhibits superior lipid lowering ability such as lower plasma total cholesterol, triglyceride, and HDL cholesterol even when used at a concentration 10,000 times lower than fenofibrate (99) (100) (101) . Its additional health benefits, such as the ability to improve the pathogenesis of NAFLD or NASH, energy metabolism, and lipid turnover in liver (100), account for the reason why it is concurrently tested for its ability to treat severe hypertriglyceridemia, dyslipidemia, T2DM, and NAFLD (99, 100) . In a recent study, Pemafibrate presented a good safety profile and corrected lipid abnormalities in a broad spectrum of patients, including those with chronic kidney disease (102) .
To date, there is no PPAR-b/d-specific agonist approved by the FDA on the market. The use of PPAR-b/d agonists in human clinical trials has been dampened after a preclinical mouse model showing protumorigenic effects, although antitumorigenic properties of PPAR-b/d have also been reported (95, (103) (104) (105) . Just recently, Seladelpar (MBX-8025; CymaBay Therapeutics, Newark, CA, USA), a novel and potent PPAR-b/d selective agonist, has been approved for a long-term clinical trial for treating conditions such as primary biliary cirrhosis and NASH (95, 106) . Seladelpar exhibits beneficial effects in treating patients with mixed dyslipidemia as well as alleviating conditions such as insulin resistance, diabetes, and atherogenic dyslipidemia (106) . Seladelpar has potential to restore physiologic hepatic lipid levels, improve liver steatosis and fibrosis, and, hence, reverse NASH pathology (106) .
Among all the PPAR-g agonists, thiazolidinedione (TZD) drugs are the most well studied, and the reason lies with their primary strength to enhance insulin sensitivity (107) . A total of 3 TZDs (troglitazone, rosiglitazone, and pioglitazone) have been FDA approved for diabetes but have been questioned because of unwanted side effects. Troglitazone (Rezulin; Pfizer, New York, NY, USA) was withdrawn from the market in 2000, just 3 yr after its launch into the market, because of the increased risk of fulminant hepatitis that ultimately results in liver failure (107) . As of 2015, the FDA has approved the usage of rosiglitazone containing T2DM medications (Avandia, Avandamet, Avandaryl, and generics) without the need for risk evaluation and dispensing restrictions because studies did not demonstrate an increased risk of heart attack as compared with conventional medicines such as metformin and sulfonylureas (108) . Pioglitazone (Actos; Takeda Pharmaceutical, Tokyo, Japan) has shown beneficial effects in the treatment of T2DM and atherosclerosis as well as prevention of cardiovascular diseases. However, pioglitazone has been associated with an increased risk of bladder cancer and bone fracture (107) . As of 2016, the FDA indeed concluded that the usage of pioglitazone (Actos, Actoplus Met, Actoplus Met XR, Duetact, and Oseni) may be linked to an increased risk of bladder cancer. Therefore, labels of pioglitazonecontaining medicines must now carry warnings about this risk and also include descriptions of the review studies conducted on this drug (109) . Several studies conducted on this drug have shown conflicting results as to whether pioglitazone truly does increase the risk of bladder cancer. Thus, the FDA recommends that health care professionals should not use pioglitazone in patients with active bladder cancer and should weigh the benefits against the risks before prescribing the drug in patients with a history of bladder cancer (109) . It was advised that patients using this drug monitor for signs and symptoms of bladder cancer such as dysuria, hematuria, and increasing urge to urinate and immediately contact their health care professional if the signs are present (109) . Hence, .50 clinical trials are currently testing this drug to test whether pioglitazone brings more benefits than harm.
Over the years, many novel PPAR drugs have been synthesized. Some of these newer drugs are not selective for any 1 particular PPAR but function as agonists for 2 or 3 PPAR isotypes and are named dual and pan-PPAR agonists, respectively (95, 97) . Although many of these drugs are not yet available on the market, some have shown great promise, and their efficacies are being evaluated via ongoing clinical trials such as Evidences IV (saroglitazar; Zydus Cadila, Ahmedabad, India) (https://clinicaltrials.gov/ identifier: NCT03061721) and Resolve-it (elafibranor, GFT505; Genfit, Loos, France) (https://clinicaltrials.gov/ identifier: NCT02704403) (110) . Elafibranor and saroglitazar are dual-PPAR agonists that have been shown to improve NASH, with favorable outcomes such as better cardiometabolic profile, lower lipid levels, and better insulin sensitivity (111) (112) (113) . Saroglitazar (trade name Lipaglyn) is approved for use in India by the Drug Controller General of India to treat diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes not controlled by statin therapy.
Bezafibrate is a pan-PPAR agonist with ongoing clinical trials and laboratory studies to establish its efficacy. Its usage has been studied in a variety of conditions, ranging from genetic disorders to acute myocardial infarctions (114) (115) (116) (117) . Bezafibrate was found to significantly lower fibrinogen levels, inflammatory responses, and cardiovascular complications in patients with acute myocardial infarction as compared with patients treated with conventional statin therapy in a clinical trial named Bezafibrami (https://clinicaltrials.gov/ identifier: NCT02291796). It has shown promising results in studies involving inherent genetic mutations. For example, X-linked adrenoleukodystrophy (ALD) (X-ALD) is a genetic condition in which there is a deficiency of the ALD protein, which results in impaired peroxisomal b-oxidation and the subsequent accumulation of very-long-chain fatty acids (115) . Although treatment of X-ALD fibroblasts with bezafibrate has shown reduced very-long-chain fatty acid levels by direct inhibition of the elongation activity (115) , the results were not reproduced when the study was conducted on a group of 10 men with X-ALD (114) . Although triglyceride levels were lowered, there were no significant changes in the very-long-chain fatty acid levels in these men (114) . However, studies of other genetic conditions have showed some promise in the usage of bezafibrate as a treatment. In patients with skeletal muscle fatty acid oxidation disorders [carnitine palmitoyltransferase (CPT) II and very long-chain acyl-coenzyme A (CoA) dehydrogenase deficiencies], bezafibrate has been shown to lower LDL, triglyceride, and free fatty acid concentrations (116) . Bezafibrate is also a potential treatment for neutral lipid storage disease with myopathy, a serious genetic disorder caused by a defect in the patatin-like phospholipase domain containing 2 gene. The gene codes for the enzyme adipose triglyceride lipase, and its defect results in the overaccumulation of lipids in tissues such as muscle, liver, and heart (117) . In a case report involving 2 sisters with neutral lipid storage disease with myopathy, a 28-wk treatment regime with bezafibrate has shown significantly promising results (117) . There were a range of metabolic improvements such as lower triglyceride levels, improved insulin sensitivity, metabolic flexibility, and, most importantly, higher fatty acid oxidation and reduced lipid accumulation in skeletal muscle, cardiac, and liver tissues (117) . The pan-action of bezafibrate thus far shows benefits in lowering free fatty acids and triglycerides but still requires more clinical trials to establish its overall efficacy and side-effect profile.
CIRCADIAN RHYTHM AND CLOCK
It is worth noting that PPAR expression and microbiota composition are oscillating in a circadian manner, suggesting the involvement of the circadian rhythm in fine-tuning microbiota and interactions with PPARs (72, 118) . In fact, biologic processes follow a circadian rhythm, an entrainable oscillation of about 24 h. One of the earliest recorded observations of circadian rhythm was in 1729, when the French biologist, Jean-Jacques d'Ortous de Mairan, noted that the leaves of the mimosa plant exhibited repeated patterns of movement in 24-h intervals despite being kept in the dark, providing evidence of an endogenous clock (119). The first circadian rhythm gene period (Per), was subsequently discovered in fruit flies in 1971 by Konopka and Benzer, firmly establishing a genetic basis for rhythmical processes (120) . Further studies unveiled the mechanisms governing the circadian rhythm, and the scientists who uncovered them, namely, Jeffrey C. Hall, Michael Rosbash, and Michael W. Young, were awarded the Nobel Prize in Physiology and Medicine in 2017 (121) . Shift workers have a higher risk of developing metabolic syndrome and its associated complications because of perturbation of their internal biologic rhythms (122, 123) . A study conducted on subjects who were subjected to shift work showed decreased leptin levels, increased glucose resistance, and reversed cortisol levels, all of which can be contributing factors to metabolic syndrome and thus indicating the importance of the circadian rhythm in good health (124) .
The circadian rhythm is regulated by an internal circadian clock that synchronizes the body's biologic functions in accordance to the day-night cycle using environmental cues, with light being the strongest synchronizer (125) . The biologic circadian clock comprises a structured hierarchical network, with circadian genes making up the lowest level of the network (126) . This group of genes comprises the circadian locomotor output cycles protein kaput (Clock), brain and muscle aryl hydrocarbon receptor nuclear translocator-like 1 (Bmal1), Per1, Per2, cryptochrome (Cry) 1, Cry2, differentiated embryonic chondrocyte (Dec) 1, and Dec2 genes. The products of these genes form the core components of the autonomous circadian clock (127) . CLOCK and BMAL1 heterodimerize (CLOCK:BMAL1) and bind to the E-box response element in the promoter of Per and Cry to up-regulate the expression of the PER and CRY proteins, which in turn accumulate, dimerize, and inhibit CLOCK and BMAL1 and hence ultimately down-regulate their own expression (125) . CLOCK and BMAL1 are also part of a second feedback loop in which the heterodimer can bind to retinoic acid-related orphan receptor (Ror) response element to positively regulate the transcription of the reverse-erb nuclear receptor (Rev-Erb) or Ror genes (128) (129) (130) . The orphan nuclear receptors REV-ERB-a and -b and ROR-a and -b, upon accumulation in the nucleus, reduce and increase Bmal1 transcription, respectively (128) (129) (130) . Similarly, the CLOCK:BMAL1 heterodimer binds to the E-box response element in the promoter of Dec1 and Dec2 to positively regulate their transcription (131) (132) (133) . DEC proteins can negatively regulate both their own transcription as well as the CLOCK: BMAL1-induced transactivation of other clock-controlled genes by either associating with the BMAL1 protein or competing with CLOCK:BMAL1 to bind to the E-box sequences in their own promoters (131) (132) (133) (134) (135) (136) . This group of circadian genes collectively forms intricate transcription and translational autoregulatory negative feedback loops to fine-tune the circadian rhythm at the molecular level.
On a cellular level, the hypothalamic suprachiasmatic nucleus (SCN) is the central regulator of the circadian rhythm (137, 138) . The SCN comprises an intrinsic intricate network of .20,000 neurons, with each neuron expressing the core clock components, making every single neuron an autonomous circadian oscillator. Fascinatingly, these neurons are coupled together and oscillate interdependently to maintain overall synchronicity and forming an oscillatory system, robust to environmental perturbations (127, 139) .
It is widely known that light is a potent zeitgeber for the SCN. It receives input directly from a novel group of photoreceptor cells known as intrinsically photoreceptive retinal ganglion cells (ipRGCs). These ipRGCs, like their name suggests, reside in the retina and express a newly discovered photopigment called melanopsin, which makes the cells photosensitive to radiations of short wavelengths (140) . The ipRGCs function as biologic transducers, which depolarize when exposed to light. The photoresponse has slow kinetics and a relatively high threshold for light, making ipRGCs an ideal group of circadian photoreceptors. The slow and robust photoresponse allows integration of light signals throughout the day, without perturbations from transient nonsolar light signals (140) . The ipRGCs integrate signals coming from the rod and cone photoreceptors and entrain the SCN upon their depolarization (141) .
Circadian oscillators were thought to be centrally mediated until the late 1990s, when circadian genes such as Per1, Per2, and Rev-ERB-a were found to be expressed in rat hepatoma cells, supporting the notion that peripheral organs may have an intrinsic circadian rhythm (142) . Another experiment also indicated that peripheral organs have their own rhythm independent of the SCN. Peripheral tissues such as the liver and skeletal muscle as well as the SCN tissue were harvested from a transgenic rat model that had the luciferase gene under the control of the Per1 promoter. As expected, in vitro culture of the SCN tissue emitted circadian rhythmic light due to luciferase expression up to 32 d and, interestingly, non-SCN tissues also emitted light rhythmically, although the rhythm lagged behind that of the SCN tissues and lessened after 2-6 d. These clearly showed that peripheral tissues have their own circadian rhythm and the SCN, a self-sustaining circadian pacemaker, entrains the oscillations of these peripheral clocks (143) . Such entrainment requires the SCN to communicate to the respective organs through both humoral and nonhumoral pathways that are necessary for rhythmic synchronization (122) . In addition, the circadian clock is closely interlinked to various metabolic pathways via complex feedback loops, resulting in circadian control of metabolism in organs such as brain, liver, skeletal muscle, and intestines (122) .
The peripheral organs and, to a lesser extent, the SCN, are also entrained by food (144, 145) . It was demonstrated that restricted feeding of mice led to rhythmicity of gene expression in their livers, pointing toward entrainment of the liver's intrinsic circadian rhythm (146) . The time of feeding and the nutrition entrain the peripheral circadian rhythm. Interestingly, dietary intake and feeding routines can affect and modulate the composition of the gut microbiota (147) . Likewise, the gut microbiota influences and is influenced by the host circadian rhythm. The composition of the gut microbiome undergoes circadian variation, and disruption of the host circadian clock via Bmal1 deletion results in the loss of rhythmicity of bacterial composition (148) . Furthermore, in GF mice, the rhythmic expression of the core clock genes Bmal1, Per1, Cry1, and Rev-Erb-b was perturbed, suggesting the regulation of liver circadian rhythm by the microbiota (72).
As mentioned above, PPARs and circadian genes have been known to function in a complex interdependent manner. PPAR-a and PPAR-g positively regulate Bmal1 transcription, and BMAL1 also up-regulates PPAR-a, forming a positive feedback loop between these 2 factors (149, 150) . It was also shown that the PPAR-a agonist fenofibrate increases the transcription of the clock genes Bmal1, Per1, Per3, and Rev-erb-a in mouse livers and cultured hepatocytes (149) . Interestingly, PER2 also associates with PPAR-a through its LXXLL motif (151) . Furthermore, DEC1 regulates lipid metabolism by repressing the transcription of Ppar-g (152, 153) through binding to the DNA-bound CCAAT/enhancer binding protein, whereas PER2 inhibits the binding of PPAR-g to the promoter of its target genes (154) . PPAR-g has been shown to induce Rev-ERBa expression by binding to the direct repeat-2 response element in the promoter region of Rev-erb-a. The nuclear receptors REV-ERB-a and ROR, in addition to being transcribed and activated by the clock proteins, regulate core clock genes and clock-controlled genes, some of which are involved in metabolic processes such as hepatic gluconeogenesis, adipocyte metabolism, and lipid metabolism (126) . Because metabolic sensors like PPARs and circadian rhythm factors are regulating each other, disruption of either 1 can lead to the development of obesity and metabolic syndrome (155, 156) . Intriguingly, drastic changes in the PPAR correlation gene networks and expression of PPAR target genes involved in metabolism are observed in GF mice, indicating a possible regulation of PPARs by the gut microbiota (72) .
All in all, it is evident that the oscillations of the gut microbiome and PPARs regulate energy homeostasis, and any perturbation to the microbiota, PPARs, or circadian rhythm can predispose to metabolic diseases (72, 118) . Currently, to the best of our knowledge, there is no review article that describes how oscillating composition of microbiota can influence PPARs in peripheral organs. Hence, in this review, we will summarize findings that indicate how the oscillating gut microbiota impacts metabolic organs of its host through PPAR, and our focus will be on 3 peripheral metabolic organs (namely, gut, liver, and muscle).
GUT

Function of the gut
The gut consists of the small intestine or the SB and the large intestine or the colon. The gut is home to the gut microbiota, and the majority of the bacteria reside mainly in the colon, making it the largest bacterial ecosystem in the body. The SB is the longest portion of the digestive tract, with a mean length of 3-5 m in humans, and consists of the duodenum, jejunum, and ileum, listed in order from the pylorus. The SB is where most of the digestion and absorption of nutrients takes place and is structured in a manner for optimal nutrient absorption (157-159). The mucosal wall of the SB, lined with simple columnar epithelial cells, is thrown into folds called plicae circulares. From the plicae, there are numerous finger-like projections called the villi. Each individual epithelial cell that lines the SB also has finger-like projections called the microvilli. These structural features of the SB tremendously increase the surface area:volume ratio for optimal nutrient absorption. Moreover, the microvasculature of the SB comprises a rich network of capillaries that lie in the submucosal layer of the SB, allowing for rapid absorption of nutrients such as amino acids, fatty acids, and monosaccharides (160) into the bloodstream and distribution to the other organs (157) (158) (159) . The SB contains a relatively lesser number of bacteria, with the major phyla being Bacteriodetes, Firmicutes, and Proteobacteria and anaerobes such as Lactobacillus species being the most predominant genera (161) . The colon, on the other hand, averages at about 1.5-2 m in humans and consists of 6 sections, beginning with the cecum and followed by the ascending colon, transverse colon, descending colon, the S-shaped sigmoid colon, and, lastly, the rectum. The main function of the colon is to absorb water and electrolytes (158) before the remaining indigestible matter is stored in the rectum for subsequent excretion. The colon is also where the majority of the gut microbiota resides and breaks down the undigested carbohydrates into SCFAs that are reabsorbed there. The colonic bacteria are also responsible for synthesizing important nutrients essential to the host such as Vitamin K, Vitamin B 12 , folic acid, and even certain amino acids such as lysine and threonine (20) .
Aside from digestion and nutrient absorption, the intestines also have an immunologic function. Their large surface area enables them to be exposed to a huge range of antigens, be it from the food or from the microbiota itself. The microbial antigens are then recognized via TLRs and Nod-like receptors located on the intestinal epithelium that subsequently either generates tolerance or an immune response from the gut's immune system. The mucosal immune system comprises the gut-associated lymphoid tissue such as Peyer's patches (located in the ileum), small intestinal lymphoid tissue, lymphoid aggregates in the colon, and immune cells spread across the lamina propria, and is located beneath the epithelial layer of the gut. These cells interact with the host's main immune system via the mesenteric lymph nodes (162) .
PPAR, microbiota, and the gut
The microbiota and PPARs have an intimate link in the gut (Fig. 2) . One of the strongest links between the trio is the SCFAs. Butyrate and propionate were shown to be strong stimulators of phosphorylation-dependent PPAR-g transcriptional activity, which is supported by several studies (35, 163, 164) , and by far, the most well-known relationship pertaining to metabolism is the butyrate-PPAR-g-ANGPTL4 pathway. This link was clearly shown in a study in which the up-regulation of ANGPTL4 in T84 and HT-29 cells was first tested via synthetic agonists of all 3 PPAR isotypes. It identified rosiglitazone as being the most potent inducer of ANGPTL4 via PPAR-g. Butyrate was then tested for stimulation by PPAR-g of ANGPTL4 production, and it was found to be higher than that induced by rosiglitazone. Moreover, inhibition of PPAR-g with the synthetic antagonist GW9662 significantly decreased ANGPTL4 expression (165) . The role of butyrate was prominent when evaluating how the gut microbiota activates PPAR-g, and a few studies evaluated the PPAR-gactivating ability of different species of bacteria and their metabolites, including but not limited to butyrate. One study showed that Firmicutes and Fusobacteria are the most potent activators of PPAR-g, with Actinobacteria causing moderate activating effects. Roseburia hominis, Roseburia intestinalis, and Fusobacterium naviforme were the top 3 species that showed the strongest PPAR-g activation via butyrate production. Atopobium parvulum and Bacteriodetes Prevotella copri were subsequently investigated for their activating abilities of PPAR-g by measuring the levels of its downstream target genes ANGPTL4 and adipose differentiation-related protein (ADRP) in HT-29 cells. These 2 species of bacteria activated PPAR-g in different ways because A. parvulum showed higher levels of ANGPTL4 6 h after the cells were exposed to the conditioned medium of the bacteria, whereas P. copri showed similar levels only after 12 h. It was postulated that the mechanism of activation was through different molecules or activating compounds because P. copri produced compounds (1-3 kDa) that were significantly smaller than those of A. parvulum (.100 kDa) (164) . The nature of these compounds remains to be elucidated. To confirm PPAR-g activation, its phosphorylation levels were measured 2 h after exposure and it was found to be increased. PPAR-g phosphorylation is mediated by ERK1/2, a well-known signaling kinase (164) . Other species of bacteria have PPAR-g stimulating effects such as Enteroccous faecalis, which increases PPAR-g1 phosphorylation and upregulation of its downstream target genes such as ANGPTL4 and ADRP (166) . Akkermansia muciniphila was found to decrease expression of PPAR-g, but not Facelibacterium prausnitzii (167) . Streptococcus salivarius secretes a bioactive compound that can suppress the transcription activity of PPAR-g on its target genes through a mechanism that is currently unknown. Supernatant collected from cultured S. salivarius displayed a dose-dependent suppressive effect on the expression of the PPAR-g target genes Angptl4 and I-FABP. The identity of this repressing bioactive compound, which is ,3 kDa, is unknown, but it is resistant to various conditions such as heat treatment (up to 100°C), protease treatment (proteinase K and trypsin), or DNase I treatment (73) .
PPAR-g expression in the ileum was also found to be associated with the BSH activity of the microbiota through a mechanism that remains to be elucidated. A total of 2 strains of E. coli producing 2 BSH variants [the strains were labeled E. coli producing BSH (ECBSH) 1 and ECBSH 2] resulted in a significant difference in PPAR-g expression (168) . ECBSH1 showed significantly more expression levels of PPAR-g than ESBCH2. The study also noted that circadian genes such as Clock, aryl hydrocarbon receptor nuclear translocator-like protein 1, Per1, Per2, and Per3 were also affected, suggesting that the expression of the clock genes can be influenced by the microbiota-modulated metabolism of bile (168) .
Another possible effect of the microbiota on metabolism is via carnitine. Carnitine, a dipeptide made from the essential amino acids lysine and methionine, is an important nutrient involved in fatty acid metabolism and generation of energy. Approximately 75% of carnitine is obtained from our diet and is absorbed from the gut via the organic cation transporters (OCTNs), mainly OCTN2, which has the highest affinity for carnitine (169, 170) . OCTN2 is a PPAR-g target gene, and because PPAR-g is regulated by the gut microbiota through LPS binding to TLR4, it was hypothesized that OCTN2 could also be regulated by the gut microbiota (169) .
PPAR-g is also implicated in the prevention of dysbiosis (171). PPAR-g blocks the expression of Nos2, which codes for the iNOS, an enzyme that produces NO in the colon. Butyrate potentiates PPAR-g signaling to inhibit the expression of iNOS and lower nitrate levels available in the colon. Without butyrate, the nitrate levels increase, driving the expansion of nitrate respiration-dependent dysbiotic bacteria. The study also elucidated other effects of butyrate. The colonocytes' main source of energy is from the b-oxidation of butyrate, resulting in heavy oxygen usage from the gut, rendering the gut environment hypoxic and favorable for obligate anaerobes. When the butyrate level falls, the colonocytes switch their energy-producing mechanism to anaerobic glycolysis, which does not require oxygen. This culminates in an increased bioavailability of oxygen in the gut, favorable for the expansion of facultative anaerobes. Interestingly, the study also demonstrated that activation of PPAR-g with Dynamic composition of the gut microbiota changes throughout the day depending on factors such as the type of food and the timing of its intake (1). The oscillating composition of microbiota regulates PPAR-g through microbe-derived SCFA-dependent and -independent pathways. In the SCFA-dependent pathway, propionate and butyrate regulate many aspects of intestinal function, including genes involved in lipid metabolism (ANGPTL4), in PPAR-g-dependent (2) and PPAR-g-independent (3) ways. Aside from lipid metabolism, activation of PPAR-g by butyrate inhibits the growth of dysbiotic bacteria via limiting the bioavailability of nitrogen in the gut lumen. Butyrate-induced activation of PPAR-g reduces nitrate oxide levels in the intestinal lumen via transcriptional repression of the NOS gene, iNOS (4). In the SCFA-independent pathway, oscillating levels of gramnegative bacteria-derived LPSs aid in fine-tuning the transcription of circadian genes (Rev-erb-a and E4BP4) through PPAR-a (5). Circadian perturbation results in a constitutive expression of cortisol-producing CYP11A1 that increases the expression of Ppar-a, which is a direct target gene of the glucocorticoid receptor (6) . The binding of LPSs to TLR activates the Ppar-a transcriptional repressor, AP-1, through the IKK-8 and JNK pathways. Different bacteria positively or negatively regulate the expression and activity of PPAR-g. A. parvulum (7) and P. copri, (8) produce PPAR-activating compounds of masses 100 kDa and 1-3 kDa, respectively, which enhance PPAR-g phosphorylation via the ERK1/2 pathway. E. faecalis phosphorylates PPAR-g1 and stimulates its activity through an unknown mechanism (9) . Different types of BSHs such as those produced by E. coli positively regulate PPAR-g expression to a different extent and impact the circadian rhythm of intestines through an unknown mechanism (10). On the other hand, the occurrence of A. muciniphila negatively correlates with the expression of PPAR-g (11) , and S. salivariusderived bioactive compounds can suppress the transcription activity of PPAR-g (12) . Altering the expression and transcriptional activity of PPAR-g impacts PPAR-g downstream targets, such as those involved in lipid metabolism (ANGPTL4 and ADRP) and energy metabolism (OCTN2) (13) . PPAR-g has been reported to counteract the proinflammatory effect of LPS via various ways. PPAR-g enhances the nuclear export of RelA, a proinflammatory subunit required for the activation of NF-kB, thus resulting in reduced NF-kB activation (14) . PPAR-g can also inhibit NF-kB expression (15) . SCFAs can suppress inflammation via a NF-kB-PPAR-g mechanism. In addition to counteracting inflammation, alteration of gut microbiota by prebiotics or probiotics promotes host defense in a PPAR-g-dependent manner (16) . Prebiotic supplementation up-regulates PGlyRP3 in a PPARg-dependent manner. PGlyRP3 mediates an anti-inflammatory effect through suppressing the NF-kB pathway, and it also has a role in host defense (17) . Probiotics and butyrate induce PPAR-g-dependent expression of the antimicrobial defensin peptides DEFB1 and mouse DefB10, which deter the growth of many pathogenic bacteria (18) . GCR, glucocorticoid receptor; MyD88, myeloid differentiation primary response 88; RE, response element; RelA, v-rel avian reticuloendotheliosis viral oncogene homolog A; RXR, retinoid X receptor.
rosiglitazone reduced the bioavailability of oxygen in the gut. Higher oxygen levels in the gut promote the expansion of dysbiotic bacteria such as Enterobacteriaceae, which is pathognomonic for epithelial gut dysfunction. Thus, factors that reduce butyrate-producing flora such as a special diet or particular antibiotics can lead to a PPAR-gmediated chain event that ultimately results in dysbiosis and gut dysfunction (171) . The microbiota also exerts inflammatory effects on the gut, which can be controlled by PPAR-g. Increased TLR4 signaling via LPS-enhanced expression of PPAR-g was observed in CaCo2 cells. To demonstrate this effect in vivo, the expression levels of PPAR-g in the colon were compared between control and GF mice, and GF mice had minimal PPAR-g expression. TLR4 signaling is associated with increased NF-kB activation, and PPAR-g promotes anti-inflammatory effects by inhibiting NF-kB-dependent transcriptional activation (172, 173) . Thus, PPAR-g has a counterinflammatory role when levels of inflammation rise (174) . However, in ulcerative colitis, although there is an increased TLR4 expression, PPAR-g expression is impaired and reduced, which leads to persistent inflammation and the etiology of this effect is unknown. If this observation explained the proinflammatory profile of the colon, it did not identify a particular cause for the reduced expression of PPAR-g (173) .
Perhaps 1 of the best established immune-modulating effects of PPAR-g is inhibiting NF-kB (61, 172) . PPAR-g suppresses the proinflammatory role of NF-kB by increasing the nuclear export of its subunit v-rel avian reticuloendotheliosis viral oncogene homolog A, also known as p65, (RelA) (61) . SCFAs also promote antiinflammatory effects by inhibiting NF-kB (163, 175, 176) . Thus, it was proposed that these SCFAs can suppress inflammation via a NF-kB-PPAR-g mechanism. So far, there is no study that directly demonstrates this mechanism. However, 1 study did report the benefits of attenuating inflammation in colitis through the supplementation of probiotics, which led to a significant increase in PPAR-g expression in the colon (174) .
Other studies have elucidated similar effects via the administration of prebiotics, which are indigestible polysaccharides that promote the growth of a healthy intestinal microbiota. Prebiotic supplementation was found to increase PPAR-g expression, which up-regulated peptidoglycan recognition protein 3 (PGlyRP3) involved in host defense (177) . The expression of PGlyRP3 was shown to be PPAR-g dependent because PPAR-g inhibition with GW9662 suppressed the PGlyRP3 response (177) . PGlyRP3 was also shown to suppress inflammatory effects by suppressing the NF-kB pathway (178) .
PPAR-g and the microbiota are also involved in the expression of antimicrobial peptides. PPAR-g was first found to directly regulate certain defensins [defensin b (DEFB) 1 and mouse DefB10], which are antimicrobial peptides of the innate immune system. It was concluded that PPAR-g was responsible for killing Candida albicans, B. fragilis, E. faecalis, and E. coli (179, 180) . Subsequently, it was shown that butyrate increased the levels of these antimicrobial peptides (181) . Probiotics and administration of Lactobacillus reuteri I5007 also resulted in higher butyrate levels, with a concomitant increase in PPAR-g expression levels and antimicrobial peptide levels in porcine small-intestine epithelial cells. Although there is an established correlation, there is so far no established causation (182) .
Up to now, descriptions of the complex interactions between residing gut microbiota, PPARs, and circadian rhythm in the gut remain incomplete. One study distinctly elucidated a dynamic relationship between the microbiota, PPAR-a, and the circadian rhythm (183) . However, these findings have not been confirmed, and the discrepancy remains to be explained (183) (184) (185) (186) (187) . Mice that underwent antibiotic depletion of the gut microbiota are known to have a constant high expression of PPAR-a and are always in a metabolically defective hypercortisol state (188) . High cortisol levels cause circadian rhythm perturbation, which results in a constitutive expression of cytochrome P450 (CYP) 11A1, a rate-limiting enzyme in cortisol synthesis as well as perhaps a positive feedback loop because PPAR-a is a direct target gene of the glucocorticoid receptor (183, 189) . Bacterial LPS is capable of repressing PPAR-a through a signaling pathway, which starts with the binding of LPS to the myeloid differentiation primary response 88 receptor (183, 190) . This receptor binding induces a cascade of events involving IKK-b and JNK signaling, which finally represses PPAR-a through activation of the PPAR-a transcriptional repressor AP-1 (183, 190) . In the absence of the gut microbiota, permanent PPAR-a activation leads to a lasting impact on the circadian rhythm of intestinal epithelial cells (IECs) by causing a constitutive expression of the circadian gene Rev-erb-a and constitutive repression in the expression of E4 promoter-binding protein 4 (E4BP4), which ultimately leads to circadian rhythm disruption in these cells. In addition, low expression of E4BP4, a CYP11A1 inhibitor, results in lasting high production of cortisol with a profound impact on host metabolism (e.g., hyperglycemia, insulin resistance, and increased circulating triglycerides and free fatty acids) (191) . The interaction between the microbiota and gut in regulating Ppar-a expression and circadian rhythm is highly complex because the level of LPS is oscillating in the gut and TLR expression also follows a circadian rhythm in IECs (183) . A balanced interaction between the circadian network and bacteria is necessary to maintain normal Ppar-a and circadian gene expression in IECs.
These current findings reveal that the close interaction between a balanced oscillating composition of the gut microbiota and PPARs is unequivocally essential to maintain many intestinal functions, including metabolism, inflammation, and immune response.
LIVER
Function of liver
The liver is the largest internal organ of the body, which developmentally originates from the foregut of the embryonic endodermal layer (192) . The liver is closely related to the gut, which is also endodermal derived. It receives 70% of its blood supply from the gut through the hepatic portal vein; hence, it is considered the second-closest organ to the gut microbiota (193) . Being an essential organ performing a wide range of functions, the liver is capable of regulating different metabolic processes such as glucose, lipid, protein, bile, and xenobiotic metabolism as well as synthesizing different factors to ensure the normal functioning of the whole body such as essential hormones (IGFs), serum proteins (albumin and globulins), and urinary proteins (major urinary proteins) (194) (195) (196) (197) (198) . The liver is the only visceral organ that is capable of regenerating itself when damaged, and this regenerative ability is highly plastic depending on the type of injury (199) . Being a highly complex immunogenic lymphoid organ, the liver is also responsible for producing systemic factors that regulate bacteria such as antimicrobial proteins and hepcidin (200) . In contrast, oscillating gut microbiota influence liver functions and physiology in many ways through PPARs, and often, perturbations in gut microbiota have been reported in many liver diseases such as NAFLD, liver cirrhosis, and hepatocellular carcinoma (201) (202) (203) . In addition, the absence of microbiota perturbs the liver PPAR gene expression network and circadian rhythm, highlighting the role of the microbiota in influencing liver physiology through PPARs (72) . Here, we have reviewed interesting findings on how the microbiota can influence liver physiology through PPAR-a and PPAR-g (Fig. 3) , and as of now, there are no findings that demonstrate how microbiota can influence liver PPAR-b/d, although our previous work indicated perturbations of the PPAR-b/d gene expression network in GF mice (72) .
PPAR, microbiota, and the liver
A few studies have indicated possible roles of the gut microbiota in influencing host energy metabolism through PPAR-a (204) (205) (206) (207) (208) . It is now known that the gut microbiota responds to nutrient deprivation by augmenting the PPAR-a-dependent fatty acid oxidation and the hepatic production of ketone bodies via the PPAR-a-dependent ketogenesis pathway (205, 209) . Furthermore, hepatocyte PPAR-a is essential for whole-body fatty acid homeostasis and is protective against NAFLD (207) . In response to food withdrawal, livers from conventionalized GF mice have a higher PPAR-a expression and ketogenic response when compared with the GF mice to supply enough energy for vital organs in the host (205) . The foodwithdrawal-induced ketogenic response is dampened in the conventionalized PPAR-a-null mice, and no significant difference is observed in fasting serum b-hydroxybutyrate levels between GF and conventionalized PPAR-a-null mice. It was concluded that PPAR-a is involved in the effect of the gut microbiota on ketosis induced by food withdrawal (205) . Aside from responding to low nutrient availability, the gut microbiota regulates liver PPAR-a during plenty of food states as well. High-fat diet (HFD)-induced NASH is alleviated upon fecal microbiota transplantation (FMT) from mice fed with control chow diet into mice fed with HFD (206) as well as in rats receiving probiotic treatment (204) . In the mouse study, hepatic PPAR-a gene expression was up-regulated 2-fold following HFD feeding, and FMT into HFD-fed mice reduced PPAR-a expression significantly, indicating an association between gut microbiota and the PPAR-a expression level (206) . In the rat study, there were lower PPAR-a protein expression levels in the liver after the rats were fed an HFD, and treatment with cholesterol-lowering probiotics was able to reverse this HFD effect (204, 208) . Despite these contradictory data, a common observation was that FMT or probiotic treatment was able to alleviate HFD-induced lipid accumulation and inflammation in the liver (204, 206) . Both HFD and food-withdrawal experiments also generated contradictory effects of gut microbiota on PPAR-a (food withdrawal: an increase of PPAR-a expression upon conventionalization; HFD: increase and decrease of PPAR-a expression upon conventionalization). The only difference between the experiments was in the composition of the microbiota that remained after conventionalization, and, therefore, it is possible that different strains of bacteria might have different regulatory roles for PPAR-a. Supportive of this, a specific microbiota genus, Lactobacillus, was effective in the treatment of fructose-induced metabolic syndrome via promoting b-oxidation through elevating PPAR-a expression, albeit only at a higher probiotic dose, suggesting that the quantity of the microbes is important as well (210) . Contradicting the theory that specific bacteria can enhance PPAR-a activity, it was shown that the gut microbiota negatively modulates the transcriptional activity of PPARa, consequently affecting the transcription of PPAR-a target genes involved in lipid metabolism, including Cyp4a belonging to the cytochrome P450s family of enzymes (211) . PPAR-a transcriptional activity, measured by the stimulation of Cyp4a10, Cyp4a31, and Cyp4a32, is higher in the GF mice than conventional mice. This stimulation is dampened after conventionalization or probiotic treatment of GF mice, suggesting that the suppressive agents are microbiota-secreted proteins or microbe-derived metabolites (211) . SCFAs are an example of how microbe-derived products can affect PPAR-a. Acetic acid, 1 of the SCFAs derived from the microbiota, has been shown to activate PPAR-a and prevent liver fat accumulation through the uncoupling protein 2 (UCP2)-a2-AMPK-mediated pathway (212) . Aside from SCFAs, the gut microbiota is also involved in modifying the composition of bile acids, another candidate that regulates liver PPAR-a. The bile acids, synthesized in the liver from their cholesterol precursors, have to be conjugated with amino acids such as glycine or taurine before entering the bloodstream and subsequently subjected to modification by microbiota for better reabsorption during their enterohepatic circulation (48, 213) . With the bacteria composition being influenced by factors such as sex, diet, host health status, and environment cues, different bacteria present in the gut are capable of inducing different modifications to the bile acids (214) . Bile acid modification by bacteria is particularly apparent by comparison with GF mice. There are vast differences in bile acid composition in the gut, liver, feces, and serum between the GF and conventionalized mice (211) . Bile acids regulate liver PPAR-a via different mechanisms in different species and can have different regulatory roles on PPAR-a. This is shown by the fact that in mice, bile acid components such as CA and CDCA are capable of attenuating the activity of liver PPAR-a and its downstream target gene expression independent of the farnesoid X receptor (FXR) (bile acid-activated nuclear receptor), whereas, contrastingly in humans, CDCA and taurocholic acid up-regulate PPAR-a expression and its target genes in hepatocytes in an FXR-dependent manner (215, 216) . Further investigation on how the specific microbiota can alter the composition of the oscillating bile acid composition and how different bile acids can regulate PPAR-a could shed some light onto how the microbiota as a whole can regulate PPAR-a expression and activity.
The gut microbiota has been shown to influence the host liver through PPAR-g as well. Liver PPAR-g activity increased upon dietary intake of Lactobacillus casei, which consequently inhibited the proinflammatory TLR-4 signaling cascade and prevented liver steatosis (217) . Although Figure 3 . Scheme showing the cascade of effects of the gut microbiota on the liver in the food-withdrawal ("fasting") and fed states. In the food-withdrawal state, the gut microbiota promotes fatty acid oxidation (ketogenesis) via increased PPAR-a expression (1) . In the fed state, opposing sets of data propose that the gut microbiota increases (2) or decreases (3) PPAR-a expression. When PPAR-a expression is decreased, PPAR-a-dependent production of proteins involved in lipid metabolism such as Cyp4a belonging to the CYP family of enzymes is also decreased (4). However, despite the contradictory data, FMT or probiotic supplementation alleviates inflammation of the liver caused by lipid accumulation (NASH). It is thought that the only difference in the composition of the microbiota might account for the different expression levels in PPAR-a (5) . Lactobacillus improves metabolic syndrome effectively by promoting b-oxidation through elevating PPAR-a expression at higher probiotic dosages (6) . PPAR-a shows a circadian expression pattern, possibly regulated by glucocorticoids (189) , which in turn is regulated by the gut microbiota (276, 277) (7) . Other factors that modulate PPAR-a include acetic acid, an SCFA produced by the microbiota that prevents liver fat accumulation through UCP2-a2-AMPK-mediated pathway bile acids (8) . In humans, CDCA and taurocholic acid (TCA) up-regulate PPAR-a in an FXR-dependent manner (9) . Interestingly, the outcomes are different in mice, in which CA and CDCA are capable of attenuating liver PPAR-a independent of FXR (10) . Notably, PPAR-g is influenced by the gut microbiota as well. With the liver's circadian rhythm being regulated by the gut microbiota, mice fed an HFD were found to have increased Firmicutes and reduced Bacteriodetes populations, which direct a phase shift and higher amplitude of Ppar-g mRNA as well as PPAR-g protein levels (11) . Rhythmicity of transcripts involved in PPAR-g-dependent amino acid and fatty acid metabolism are also affected (12). The 2-way arrow shows that PPAR-g is responsible for HFD-induced alteration in liver circadian rhythm (13) . Metabolites produced by the microbiota affect both PPAR-g and the circadian rhythm, and a balance of the microbiota metabolites is essential to maintain the normal physiology of the liver. Propionate and butyrate, SCFAs produced by the microbiota, activate PPAR-g (14) , which results in increased UCP2 expression (15) and leads to the activation of AMPK, an autophagy regulator, maintaining hepatic homeostasis. Other metabolites such as amino acids and polyamines also regulate the circadian rhythm (16) . Lastly, L. casei, is thought to increase the fermentation of propionic acids with the help of Propionibacteria (17) and to increase the activity of PPAR-g to inhibit the proinflammatory TLR-4 signaling cascade (18) , thereby preventing hepatic steatosis.
the mechanism is still unknown, the synergistic interaction between L. casei and Propionibacterium shermanii accelerated the fermentation of propionic acid, which is an activator of PPAR-g (163, 218) . Microbe-derived propionate and butyrate promote hepatic autophagy, which is essential for normal turnover and maintenance of hepatic homeostasis by increasing UCP2 expression through the activation of PPAR-g that consequentially activates AMPK, an autophagy regulator (219, 220) . Both PPAR-g and PPAR-a in the liver have been found to exhibit some form of rhythmicity. A number of studies have elucidated how the rhythmic expression of PPAR-g is affected by the gut microbiota. Dynamic composition of the gut microbiota regulates the liver circadian rhythm and reprograms liver transcriptomics in response to nutritional cues. Mice fed with HFD were found to have increased Firmicutes and reduced Bacteriodetes populations in their gut microbiota (221, 222) . Fecal transplantation of the HFD-associated gut microbiome into antibiotic-treated conventional mice directed a higher rhythmicity in PPARg mRNA expression, with a previously unobserved amplified zenith at zeitgeber time 12 as well as a higher PPAR-g protein level in the liver (118, 204) . It was further shown that PPAR-g is responsible for HFD-induced alteration of the liver circadian rhythm, as shown by the phase advancement in the expression of core clock and clock target genes (Bmal1, Per2, Rev-erb-a, and Dbp) and the increase in lipogenic gene expression that resulted in lipid accumulation in the liver despite a normal chow diet; all of which can be reversed with either a PPAR-g antagonist or antibiotic treatment (118) . Similar to the GF mice, antibiotic treatment kick-started de novo rhythmicity of 912 transcripts, some of which were involved in the PPAR-g signaling pathway and amino acid and fatty acid metabolisms as well as loss of rhythmicity in some others; for example, glucose phosphate isomerase-1 (223) . Depletion of gram-positive bacteria via vancomycin affected liver circadian rhythm documented by the changes in the expression of core circadian genes, circadian-regulated proteins, and metabolites (224) . Mechanistically, amino acids and polyamines synthesized by the gut microbiota or those derived from the diet regulate the circadian rhythm. The use of either antibiotic treatment or a polyaminedeficient diet was enough to reverse the loss or gain of rhythmicity observed in HFD-fecal transplant experiments (223) . A role of the microbiota in regulating liver PPAR-g was shown by using a commercial probiotic drink containing the L. casei strain Shirota (225) to treat fructoseinduced liver steatosis in a mouse model (217) .
As for PPAR-a, its transcription in liver presents a daily rhythm with involvement of Clock:Bmal1 and its target genes and is likewise regulated by the gut microbiota. This rhythm is perturbed in GF mice (72, 226) . Although there is an established link between the gut microbiota and the pathways that affect the daily expression of liver PPAR-a, there are no findings that depict the direct impact of the gut microbiota on the receptor's circadian expression.
All in all, the above-mentioned findings indicate that the gut microbiota, although residing at a distance from the liver, is capable of influencing PPAR expression in the liver. The data indicate that different strains of bacteria regulate the liver PPAR expression differently, and the circadian oscillation of these bacteria is henceforth crucial for liver physiology and maintaining whole-liver homeostasis.
SKELETAL MUSCLE
Function of skeletal muscle
Skeletal, cardiac, and smooth muscles are the 3 major muscle types in the body, with skeletal muscle being the most abundant muscle, accounting for 40-50% of the body's total mass (29, 227, 228) . Skeletal muscle can be broadly classified into either type 1 slow-twitch fibers that generate smaller contractile force aerobically for a prolonged period of time or type 2 fast-twitch fibers that generate stronger contractile force anaerobically for a shorter period because of fatigue (229, 230) . Type 2 muscle is further subdivided into type 2a, 2x, and 2b, each subtype with its own force production and fatigue-resistance capability. Type 1 and type 2a muscles are also called oxidative muscles because these muscles predominantly use oxidative phosphorylation to synthesize ATP (229, 230) . On the other hand, type 2x and 2b generate ATP via glycolytic pathways instead (231) . Although the primary function of skeletal muscle is to change posture and locomotion, it has an integral role in metabolism and overall systemic health. Long-term food withdrawal would lead to muscle wasting because muscle proteins will be used for energy production via hepatic gluconeogenesis (232, 233) . In addition, the skeletal muscle is a major organ in glucose homeostasis, taking up and storing up to 80% of postprandial glucose via insulin-mediated processes. Gut dysbiosis disrupts the physical and metabolic function in muscles through microbial products such as LPS (29) and gut microbe-derived extracellular vesicles that impair glucose metabolism in skeletal muscle (234) . These microbial products leak into the systemic circulation, prompting a proinflammatory response via the release of inflammatory cytokines such as TNF-a and IL-6, culminating in smaller, fat-infiltrated muscles with disrupted insulin signaling pathways and eventually leading to the pathogenesis of metabolic syndrome and sarcopenia (235) (236) (237) (238) (239) (240) (241) .
PPAR, the gut microbiota, and muscle
A variety of experiments and studies have addressed the influence of the gut microbiota on PPARs in skeletal muscle (Fig. 4) . Conventionalized mice treated with metronidazole, a class of antimicrobial drug that targets anaerobic bacteria, demonstrated the significant impact of an altered gut microbiota on the skeletal muscle (242) . Metronidazole treatment led to an increase in Proteobacteria in mouse feces. In parallel, in comparison to the metronidazoletreated GF mice, the conventionalized mice had a decrease in larger myofibers and an increase in smaller myofibers in the tibialis anterior, and a gene expression analysis of the gastrocnemius muscle revealed an up-regulation of genes involved in muscle atrophy, such as hdac4, atrogin 1, myogenin, and muscle-really interesting new gene-finger protein-1. These changes suggest that the gut microbiota could be contributing to the overall sarcopenic atrophy in the hind limb muscle mass of the mice. The abovementioned studies therefore provide evidence for the gut microbiota's various impacts on skeletal muscle metabolism and physiology. A biochemical analysis of the gastrocnemius muscles of GF and conventionalized mice showed an increase of tricarboxylic acid cycle (TCAC) intermediates in the conventionalized mice but with no significant augmentation in high-energy phosphate stores (11) . The TCAC in the mitochondrial matrix is the most important metabolic pathway in animals, accounting for two-thirds of the total energy produced via the generation of high-energy phosphate stores such as in the form of ATP (243) . Despite a higher TCAC activity in conventionalized mice compared with GF mice, there is a minimal effect on the amount of energy produced, indicating a decrease in metabolic efficiency in the skeletal muscle. GF mice were more metabolically efficient compared with their conventionalized counterparts because of higher levels of AMPK activity in their skeletal muscle (10) . AMPK is an enzyme that monitors the cellular energy status and is activated during situations of metabolic stresses, especially when there is an increased AMP:ATP ratio. Under such circumstances, AMPK is then activated via phosphorylation to suppress ATP-consuming anabolic processes and promote ATP-producing catabolic processes (244) . In GF mice, the phosphorylated AMPK level was 40% higher, promoting ATP production by increasing proteins involved in catabolism while switching off biosynthetic pathways, which conserves ATP. Therefore, mice are metabolically more efficient in the absence of the microbiota (10) . Some of these processes can be attributed to fatty acid oxidation due to AMPK activation. Higher phosphorylated AMPK level in the GF mice can result in a decreased concentration of malonyl CoA, a coenzyme involved in fatty acid chain elongation (245) . Malonyl CoA is also an inhibitor of CPT-1, an enzyme that regulates the transfer of fatty acids into the mitochondria for oxidation (10, 246) . Logically, in the GF mice, more Figure 4 . Scheme showing the influences of the gut microbiota on the skeletal muscle, mainly via bacterial metabolites it produces. SCFAs activate AMPK by either increasing the AMP:ATP ratio in the skeletal muscles directly (1) or by activating FFAR2 (Ffa2) and FFAR3 (Ffa3) in the adipose tissue (2) . Activation of these receptors results in increased secretion of leptin, which in turn increases the AMP:ATP ratio in the skeletal muscle. An increase in the AMP:ATP ratio is an indicator of metabolic stress and AMPK, which monitors the cellular energy status, and is activated during such situations via phosphorylation (3). AMPK activation then results in the suppression of ATP-consuming anabolic processes and the promotion of ATP-producing catabolic processes (4) . AMPK can also be directly activated by butyrate, 1 of the SCFAs produced by the gut microbiota (5) . Exercise increases the proportion of the butyrate-producing phylum Firmicutes in the gut, which results in higher levels of butyrate and higher AMPK activity (6) , leading to an up-regulation of fatty acid oxidation processes by inhibiting malonyl CoA to increase CPT-1 activity (7) . The up-regulation of fatty acid oxidation is also achieved by AMPK increasing the expression of PPAR-a, responsible for the transcription of genes involved in the oxidation process such as Cpt-1 (8) . Butyrate also enhances the expression and activation of PPAR-b/d via AMPK and PGC-1a (9) . PPAR-b/d activation subsequently leads to enhanced fatty acid metabolism in muscle (10), a shift toward oxidative muscle fibers (11), and an overall decrease in body fat content (12) . Lastly, the gut microbiota also suppresses ANGPTL4, an inhibitor of LPL, leading to minimal storage of triglycerides (13) . ANGPTL4 also induces PGC-1a, a transcription factor known to control the activity of all 3 PPAR isotypes (14) .
AMPK activation will eventually lead to higher activity of CPT-1, allowing for more fatty acids to undergo oxidation and produce more energy. Initially, this was thought to be the only mechanism, but it was subsequently discovered that AMPK activation increases expression of PPAR-a, leading to increased transcription of genes involved in fatty acid oxidation such as CPT-1 (71, 90, (246) (247) (248) . Integrating these data, it seems that the absence of the microbiota culminates in an increase in fatty acid oxidation through the AMPK-PPAR-a pathway. However, contradictory results suggested that the presence and not the absence of the microbiota up-regulates AMPK activation, with the same outcome of inducing higher PPAR-a expression in muscle (33) . Additional studies show that the SCFAs produced by the microbiota are distributed to the peripheral organs, including the skeletal muscle via systemic circulation. These SCFAs activate AMPK by either increasing the AMP:ATP ratio in skeletal muscles (249) (250) (251) or by activating specific G-protein receptors (GPRs) called free fatty acid receptor (FFAR) 2 and FFAR3 (previously known as GPR43 and GPR41, respectively) in adipose tissues, where they are highly expressed (33) . Activation of these receptors in the adipose tissues resulted in enhanced secretion of leptin, an adipokine that regulates satiety and energy expenditure (33) . Increased plasma leptin level subsequently raises the AMP:ATP ratio in the skeletal muscle, which up-regulates fatty acid b-oxidation via enhancing AMPK-dependent activation of PPAR-a (33) .
It seems counterintuitive that the absence of the microbiota elevates AMPK-PPAR-a activation, with the GF mice being the metabolically superior model. However, this is also explained in the very same study by an AMPK-independent mechanism (33). The gut microbiota is known to suppress ANGPTL4, an inhibitor of LPL, which is the enzyme responsible for storage of triglycerides. Without the gut microbiota to suppress ANGPTL4, high levels of ANGPTL4 profoundly inhibit LPL, allowing minimal storage of triglycerides (10) . Elevated ANGPTL4 also induced PGC-1a, a transcription coactivator known to control the activity of all 3 PPAR isotypes (10, 33) and thereby increase fatty acid metabolism. Now, there is a clear distinct axis between the gut microbiota and the skeletal muscle. Intuitively, the effects of influencing SCFA concentration should cascade down to PPARs in the skeletal muscle, affecting fatty acid metabolism, and because the SCFAs are largely produced by the gut microbiota, factors that influence the gut microbiota should affect the SCFA profile. Examples of these factors include exercise, diet, pregnancy, antibiotic use, stress, and age (250) . It should be noted that diet itself can cause changes to the SCFA profile (34, 252) .
In addition to PPAR-a, PPAR-b/d has been reported to be influenced by the gut microbiota as well (33, 249, 251) . An increase in microbe-derived butyrate levels is associated with higher PPAR-b/d expression in the skeletal muscle (251) . Butyrate treatments conducted in mice and the rat skeletal myoblast L6 cell line increased the level of PPAR-b/d in both the skeletal muscle and the cell line. This observation suggests a role of gut microbiota in regulating PPAR-b/d expression in skeletal muscle cells through butyrate, which is produced in an oscillating manner, via promoting energy expenditure and inducing mitochondria function (251) . PPAR-b/d is responsible for stimulating fatty acid metabolism in muscle, and therefore altering PPAR-b/d expression can have a huge impact on muscle physiology. Higher PPAR-b/d expression correlates with a shift toward oxidative muscle fibers, higher rates of oxidative capabilities, and an overall decrease in body fat content (253) (254) (255) (256) . The absence of PPAR-b/d was also found to result in a reduced amount of oxidative fibers, leading to lower oxidative capabilities and insulin resistance (257) . During exercise, PPAR-b/d expression increased in the skeletal muscle, and PPAR-b/d promotes exercise endurance by preserving glucose (231, 253, 258) . Interestingly, athletes and active animals were found to have a higher butyrate level and a higher proportion of the butyrate-producing phylum Firmicutes in their gut (34, 259) . A possible mechanism for how butyrate can activate PPAR-b/d might be through the AMPK-PGC-1a pathway (260, 261) because as mentioned above, treatment of L6 cells with butyrate suggested a direct activation of AMPK (251) . Thus, the butyrate produced by the microbiota could be the factor that activates AMPK, and via that pathway, PPAR-b/d expression is stimulated, which subsequently leads to the increased oxidative capacity of the skeletal muscle (257) . However, there is no report so far that confirms a direct involvement of butyrate in this mechanism. Nevertheless, the effect of the gut microbiota on exercise has been studied. Comparison of the endurance swimming performances of specific pathogen-free (SPF) mice, B. fragilis gnotobiotic mice, and GF mice showed that the GF mice had the shortest swimming time among the 3 groups, indicating that they are less able to sustain prolonged periods of activity (262) . Although the study shows a significant impact of the gut microbiota on exercise, it was not determined whether the result was due to reduced oxidative capacity via reduced PPARb/d and butyrate levels, as postulated above.
There have been minimal studies on the effect of the gut microbiota on PPAR-g; however, there are a couple of possible mechanisms. A study showed an associated increase in PPAR-g transcript levels in FXR and small heterodimer partner-knockout mice when fed an HFD. This translated into the mice having higher fat metabolizing capacity and mitochondrial function with an associated increase in type 1A muscle fibers, resulting in greater physical activity overall (263) . In fact, in a separate study involving SPF and GF mice, it was also shown that both in vivo and in vitro administration of SCFAs were able to partially rescue observed muscle atrophy phenotype and promote myogenic gene expression in GF mice. Restoration of neuromuscular junction function in muscle to a level comparative to that of the SPF in GF mice is possible with conventionalization, suggesting the possible role of gut microbiota in muscle development and function (264) . It is possible that the gut microbiota may have an effect on the skeletal muscle's function via FXR-PPAR-g pathway; however, this needs to be confirmed. It was also demonstrated that FXR inhibits PGC-1a levels in the skeletal muscle (265) , and thus there is a possibility that the gut microbiota may exert its effects on PPARs via this mechanism as well.
Studies have shown that HFD-induced obesity is associated with an increased Firmicutes:Bacteroidetes ratio (12, 118, 204) . This is counterintuitive to the fact that exercise also increases the amount Firmicutes with decreased fat content. A possible explanation is that the HFD decreased bacterial phylotype richness and fecal SCFA concentrations because of lower levels of carbohydrates in the diet (252, 266) . Lower SCFA levels would result in lower levels of PPAR-b/d expression in the muscles, which would reduce their oxidative capacity. Although this process has not been demonstrated, SCFAs were able to prevent HFD-induced obesity (266) .
With respect to the microbiota's impact on PPAR and the circadian rhythm, there have yet to be many studies that discern this particular relationship in the skeletal muscle. However, conventionalized mice treated with metronidazole, leading to Proteobacteria in mouse feces, perpetuated changes in the metabolic and circadian profiles of the gastrocnemius muscle. Expression of PPAR-g and its target gene adiponectin as well as circadian clock genes Per2, Cry2, Ror-b, and E4BP4 were all up-regulated in the skeletal muscle of the treated SPF mice but not in GF mice (242) . How this impacts mice physiologically and metabolically is yet to be elucidated.
Hence, the gut microbiota is capable of influencing the muscle in a timely manner. The oscillating composition of these factors regulate mainly energy homeostasis and, interestingly, muscle type switching through PPARs. Most of the findings revealed that the key gut microbe-derived factor to be the SCFAs, although there might be other microbe-derived factors and mechanisms of regulation by the gut microbiota that remain unexplored.
CONCLUSIONS
Accumulating evidence suggests that the microbiota plays a role in metabolic syndrome modulation, and gut microbiota-derived factors influence PPARs and circadian rhythmicity in different metabolic organs. In support of this conclusion, PPARs have been shown to play significant roles in mediating metabolic and circadian rhythm effects of the microbiota in these organs, particularly in the intestines, liver, and muscle as reviewed in this article. So far, PPAR-a and PPAR-g have been more intensively studied in these metabolic organs, whereas the role of PPAR-b/d in modulating circadian and metabolic signals from the microbiota remains less well understood. With the current rising interest in using prebiotics, probiotics, synbiotics, or even gut microbiota transfer to fine-tune the gut microbiota to treat patients, further understanding of how the microbiota can differentially impact the host metabolic organs and overall physiology is vital for optimum treatment. 
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